[Expert consensus on disease-modifying therapy for Alzheimer's disease].

Abstract

Alzheimer's disease (AD) poses a significant challenge to China's aging population, and treatment is now comprehensively shifting toward disease-modifying therapy (DMT). By targeting core pathophysiological mechanisms, DMT seeks to alter the natural progression of AD. As an emerging therapeutic paradigm, there is an urgent need for expert consensus to standardize the clinical use of DMT drugs in AD. This consensus systematically reviews both clinical practice and research advancements related to DMT for AD, including its target populations, contraindications and high-risk groups, pre-treatment evaluation procedures, administration methods and durations, efficacy assessments, and adverse event monitoring. It presents 17 recommendations to guide the clinical application of DMT in AD.